Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 910 results for "novartis"

Cipla wants Novartis's patents on respiratory drug revoked

Top corporate news of the day - October 31, 2014

Cipla , which has launched its own version of the Novaritis 's respiratory drug Indacaterol sold under the Onbrez brand, has asked DIPP to revoke five patents of Novartis relating to the product citing need for public health access and stated the ... India Infoline, 17 hours ago
Cipla drug kicks off patents row Asian Age, 22 hours ago

164 images for novartis

PharmaceuticalProcessing, 2 days ago
India TV, 1 day ago
NDTV Profit, 1 day ago, 3 days ago
WTVD Raleigh Durham, 1 day ago
The Local Switzerland, 3 days ago
North, 3 days ago
Reuters UK, 1 day ago
Yahoo! News, 1 day ago
Reuters, 1 day ago

New Issue- Novartis prices dual tranche deal

Oct 31(Reuters) -Following are terms and conditions of a dual tranche deal priced on Friday. Borrower Novartis Finance SA Guarantor Novartis AG * * * * Tranche 1 Issue Amount 600 million euro ...
 Reuters6 hours ago

Vaccine manufacturer Novartis likely not to benefit from emergency deal with Princeton

Novartis spokeswoman Julie Masow said the company has filed an Investigational New Drug application with the FDA, although it has yet to reach an agreement with the agency on a pathway to licensure. Under the just-announced vaccination plan, ...
 Individual.com20 hours ago

Updated: Having obtained safety data, Novartis seeks licensure for Bexsero vaccine in the U.S.

Novartis -- the manufacturer of Bexsero, the meningitis B vaccine used to vaccinate University students this spring -- announced that it is currently filing an application for FDA review of its vaccine, in the hopes of obtaining licensure. The use ...
 Individual.com20 hours ago

Novartis BNP Paribas Primary New Issues : Stabilisation Notice

Date: 31st October, 2014 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. Issuer: Novartis Finance S.A. Pre Stabilisation Notice BNP Paribas ...
 EuroInvestor12 hours ago REG-Novartis no stab BNP Paribas Primary New Issues : Stabilisation Notice  Reuters6 hours ago REG-Novartis BNP Paribas Primary New Issues : Stabilisation Notice  Reuters12 hours ago Novartis no stab BNP Paribas Primary New Issues : Stabilisation Notice  EuroInvestor6 hours ago

Novartis net profit jumps by 45% in Q3 to $3.2 bn

Novartis International AG, a world leader in the pharmaceutical segment, has posted strong financial performance during the third quarter ended September 2014. Its net earnings went up sharply by 45.1 per cent to $3,240 million from $2,233 million ...
 PharmaBiz1 day ago Novartis results top projections as new products gain momentum  The Gulf Today1 day ago Novartis Posts Strong Third-Quarter Results; Cost-Cutting Efforts Pay Off  Bidness Etc3 days ago Novartis Profit Beats Estimates as New Drugs Offset Diovan  La Repubblica3 days ago

Novartis, Taiwan Semi Tough to Beat Says Aberdeen Fund Manager

Novartis shares will move higher due to the pharma giant's strong pipeline and healthy dividend, said Martin Connaghan, portfolio manager for the Aberdeen International Equity Fund. Connaghan added that Novartis is benefiting from its exposure to ...
 TheStreet.com1 day ago

Novartis India to hold board meeting

This page uses frames, but your browser doesn't
 Capital Market1 day ago

FDA News Roundup: Merck, Eisai, Novartis, And More

By , associate editor Novartis Secukinumab Recommended For Approval In a unanimous vote, The Dermatologic and Ophthalmic Drugs Advisory Committee voted to support the approval of AIN457 (secukinumab) for adults suffering from ...
 Pharmaceutical Online1 day ago
Seeking Alpha

Novartis: Continued Operating Strength, Shares Fairly Valued

Summary Novartis' third quarter operating results indicated continued pricing strength despite ongoing patent losses and pressure from generics, with growing revenues in emerging markets. The company's pipeline remains robust, and I expect the ...
 Seeking Alpha1 day ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less